Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes

被引:9
|
作者
Tong, Yan [1 ]
Huang, Jian Qing [1 ]
Chen, Yang [1 ]
Tu, Mei [1 ]
Wang, Wei [1 ]
机构
[1] Fujian Med Univ, Longyan Affiliated Hosp 1, Longyan, Fujian, Peoples R China
关键词
liraglutide; sitagliptin; bowel preparation quality; gastrointestinal discomfort; gastrointestinal motility; DOSE POLYETHYLENE-GLYCOL; GLUCOSE; COLONOSCOPY; EXENATIDE; SUPERIOR; MOTILITY; TRANSIT;
D O I
10.3389/fphar.2023.1176206
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms. Hence, this observational study mainly aimed to assess the influence of GLP-1 RAs liraglutide and DPP-4i sitagliptin on bowel preparation in type 2 diabetes (T2DM). Method: This observational study consecutively enrolled T2DM scheduled for a colonoscopy. Participants were prospectively separated into the liraglutide group (n = 120), sitagliptin group (n = 120), and control group (n = 120) based on the current hypoglycemic regimen. 3L split-dose polyethylene glycol regimens were used for bowel preparation. Experienced gastrointestinal endoscopists conducted colonoscopies. Lawrance Bowel-Preparation Tolerability Questionnaire and Boston Bowel Preparation Scale (BBPS) were conducted to assess bowel cleaning quality, tolerability, and safety. Results: The incidence of inadequate bowel cleaning was 17.5% in the liraglutide group, 20.5% in the sitagliptin group, and 21.7% in the control group. The difference among the three groups was not statistically significant (p = 0.927). Meanwhile, there were no significant differences in the mean BBPS, cecal intubation time, and polyp-detecting rates among the three groups (all p > 0.0.05). Nausea, vomiting, and bloating scores were increased in the liraglutide group compared with the other two groups (p < 0.05), whereas most were mild or very mild. Subgroup analyses showed that the incidence of inadequate bowel cleaning in T2DM with diabetic peripheral neuropathy (DPN) was increased in the liraglutide group compared with the sitagliptin group (61.3% vs. 32.1%, p = 0.022) and control group (61.3% vs. 32.8%, p = 0.025). Conclusion: GLP-1RA liraglutide or DPP-4i sitagliptin did not significantly increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms during bowel preparation. Liraglutide may increase the incidence of inadequate bowel preparation in patients with DPN. This study reveal that more attention and aggressive bowel preparation regimens should be given to the T2DM with DPN.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
    Campos, Carlos
    Unger, Jeff
    POSTGRADUATE MEDICINE, 2021, 133 (08) : 843 - 853
  • [22] The addition of metformin and glucagon-like peptide-1 receptor agonist or dipeptidyl-peptidase-4 inhibitor to insulin for latent autoimmune diabetes in adults
    Sumie Moriyama
    Hidekatsu Yanai
    International Journal of Diabetes in Developing Countries, 2014, 34 : 56 - 56
  • [23] The addition of metformin and glucagon-like peptide-1 receptor agonist or dipeptidyl-peptidase-4 inhibitor to insulin for latent autoimmune diabetes in adults
    Moriyama, Sumie
    Yanai, Hidekatsu
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2014, 34 (01) : 56 - 56
  • [24] Abelmoschus esculentus subfractions improved nephropathy with regulating dipeptidyl peptidase-4 and type 1 glucagon-like peptide receptor in type 2 diabetic rats
    Peng, Chiung-Huei
    Lin, Hsing-Chun
    Lin, Chih-Li
    Wang, Chau-Jong
    Huang, Chien-Ning
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2019, 27 (01) : 135 - 144
  • [25] Association between the use of glucagon-like peptide 1 agonist and the risk of psoriasis in diabetes patients compare to dipeptidyl peptidase-4 inhibitors in Taiwan
    Chang, Kai-Cheng
    Huang, Hao-Hsin
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 157 - 157
  • [26] Effects of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, on Colorectal Carcinogenesis in a Model of Type 2 Diabetes
    Inoue, Takuya
    Yorifuji, Naoki
    Fujiwara, Kaori
    Sakanaka, Taisuke
    Iguchi, Munetaka
    Narabayashi, Ken
    Okada, Toshihiko
    Nouda, Sadaharu
    Kakimoto, Kazuki
    Ishida, Kumi
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Umegaki, Eiji
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2014, 146 (05) : S654 - S655
  • [27] The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
    Kubota, Yoshiaki
    Miyamoto, Masaaki
    Takagi, Gen
    Ikeda, Takeshi
    Kirinoki-Ichikawa, Sonoko
    Tanaka, Kotoko
    Mizuno, Kyoichi
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (11) : 1364 - 1370
  • [28] EFFECT OF THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR SITAGLIPTIN IN OLDER ADULTS WITH TYPE 2 DIABETES MELLITUS
    Stafford, Sara
    Elahi, Dariush
    Meneilly, Graydon S.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 (06) : 1148 - 1149
  • [29] Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus
    Holst, JJ
    Deacon, CF
    CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (06) : 589 - 596
  • [30] Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
    Nauck, Michael A.
    Meier, Juris J.
    Cavender, Matthew A.
    Abd El Aziz, Mirna
    Drucker, Daniel J.
    CIRCULATION, 2017, 136 (09) : 849 - U176